The European Commission has announced that AstraZeneca will stop marketing its Covid-19 vaccine, Vaxzevria, in the EU starting tomorrow. This decision comes after the company submitted a withdrawal request on March 5, citing the lack of demand for the vaccine and the surplus of other vaccines on the market as reasons for the withdrawal.
AstraZeneca acknowledges the role that Vaxzevria has played in helping to combat the pandemic, stating that more than 6.5 million lives were saved and over 3 billion doses were supplied worldwide in the first year of use alone. However, with numerous updated vaccines now available for Covid-19 variants, there is a surplus of vaccines in the market, leading to a decrease in demand for Vaxzevria.
The company emphasizes that this decision is in response to changing dynamics of the vaccine market and reflects their belief that it is no longer being produced or supplied. As such, they have decided to withdraw Vaxzevria from the EU market.
